MX2024012081A - Formulaciones de nicotina - Google Patents

Formulaciones de nicotina

Info

Publication number
MX2024012081A
MX2024012081A MX2024012081A MX2024012081A MX2024012081A MX 2024012081 A MX2024012081 A MX 2024012081A MX 2024012081 A MX2024012081 A MX 2024012081A MX 2024012081 A MX2024012081 A MX 2024012081A MX 2024012081 A MX2024012081 A MX 2024012081A
Authority
MX
Mexico
Prior art keywords
nicotine
salt
powder
nicotine formulations
chemically bonded
Prior art date
Application number
MX2024012081A
Other languages
English (en)
Spanish (es)
Inventor
Håkan Engqvist
Jesper Lööf
Original Assignee
Emplicure Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB2204804.5A external-priority patent/GB2613211B/en
Priority claimed from GB2208809.0A external-priority patent/GB2619747A/en
Application filed by Emplicure Ab Publ filed Critical Emplicure Ab Publ
Publication of MX2024012081A publication Critical patent/MX2024012081A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/42—Treatment of tobacco products or tobacco substitutes by chemical substances by organic and inorganic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B13/00—Tobacco for pipes, for cigars, e.g. cigar inserts, or for cigarettes; Chewing tobacco; Snuff
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/281—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed
    • A24B15/283—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed by encapsulation of the chemical substances
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/281—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed
    • A24B15/283—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed by encapsulation of the chemical substances
    • A24B15/284—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed by encapsulation of the chemical substances the additive being bound to a host by chemical, electrical or like forces, e.g. use of precursors, inclusion complexes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/287—Treatment of tobacco products or tobacco substitutes by chemical substances by inorganic substances only
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Seasonings (AREA)
MX2024012081A 2022-04-01 2024-09-30 Formulaciones de nicotina MX2024012081A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2204804.5A GB2613211B (en) 2022-04-01 2022-04-01 Alkaline oral formulations
GB2208809.0A GB2619747A (en) 2022-06-15 2022-06-15 Nicotine formulations
PCT/EP2023/058710 WO2023187223A1 (en) 2022-04-01 2023-04-03 Nicotine formulations

Publications (1)

Publication Number Publication Date
MX2024012081A true MX2024012081A (es) 2025-01-09

Family

ID=86095906

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024012081A MX2024012081A (es) 2022-04-01 2024-09-30 Formulaciones de nicotina

Country Status (9)

Country Link
US (1) US20250280866A1 (https=)
EP (1) EP4504145A1 (https=)
JP (1) JP2025513762A (https=)
KR (1) KR20250011902A (https=)
CN (1) CN119212682A (https=)
AU (1) AU2023242616A1 (https=)
CA (1) CA3246985A1 (https=)
MX (1) MX2024012081A (https=)
WO (1) WO2023187223A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210169123A1 (en) * 2019-12-09 2021-06-10 Nicoventures Trading Limited Pouched products with enhanced flavor stability
WO2026068838A1 (en) * 2024-09-30 2026-04-02 Jt International Sa A nicotine source

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2219287A (en) * 1938-01-22 1940-10-29 Tobacco By Products And Chemic Insecticide and process of making the same
JPH10114897A (ja) * 1996-10-11 1998-05-06 Sangi Co Ltd 粉末香料、その製造方法及びその応用
GB0909460D0 (en) * 2009-06-02 2009-07-15 Intrinsiq Materials Global Ltd Mesoporus material
US9848634B2 (en) * 2009-06-30 2017-12-26 Philip Morris Products S.A. Smokeless tobacco product
CN101966165B (zh) * 2009-07-14 2012-06-13 无锡健而乐医药科技有限公司 口腔吸收固体泡腾制剂
SE535587C2 (sv) 2011-03-29 2012-10-02 Chill Of Sweden Ab Produkt innehållande ett fritt nikotinsalt och en ej vattenlöslig påse
JP5719932B2 (ja) * 2011-07-15 2015-05-20 日本たばこ産業株式会社 香料担持低吸着性粒子、シガレット用フィルタ、フィルタ付きシガレットおよび香料担持低吸着性粒子の製造方法
CN103284318B (zh) * 2013-06-20 2015-03-11 中国烟草总公司山东省公司 一种舌下烟及其制备方法
WO2015193379A1 (en) * 2014-06-18 2015-12-23 Swedish Match North Europe Ab A tobacco or non-tobacco product comprising magnesium carbonate
CN105646069A (zh) * 2015-12-30 2016-06-08 民勤县巴腾生物有机肥料有限公司 一种多效生物有机颗粒肥及其制备方法
CN107259635A (zh) * 2017-06-16 2017-10-20 云南中烟工业有限责任公司 一种烟碱复合盐含化片及其制备方法
GB201714412D0 (en) * 2017-09-07 2017-10-25 Emplicure Ab Evaporation devices containing plant material
WO2019110073A1 (en) 2017-12-08 2019-06-13 Fertin Pharma A/S Solid oral nicotine formulation
CA3085065C (en) * 2017-12-08 2023-12-05 Fertin Pharma A/S Formulations providing high nicotine concentrations
CN110680884A (zh) * 2018-07-06 2020-01-14 高全良 一种止牙痛的药粉及其制备方法
JP2022519542A (ja) * 2019-02-01 2022-03-24 スウィーディッシュ・マッチ・ノース・ヨーロップ・アーベー ｐＨ調整剤を含む経口用ニコチン製品
US20210169123A1 (en) * 2019-12-09 2021-06-10 Nicoventures Trading Limited Pouched products with enhanced flavor stability
US11826462B2 (en) * 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
GB202105305D0 (en) * 2021-04-14 2021-05-26 Zanoprima Lifesciences Ltd Supported nicotine composition

Also Published As

Publication number Publication date
JP2025513762A (ja) 2025-04-30
CN119212682A (zh) 2024-12-27
WO2023187223A1 (en) 2023-10-05
EP4504145A1 (en) 2025-02-12
KR20250011902A (ko) 2025-01-22
AU2023242616A1 (en) 2024-11-14
CA3246985A1 (en) 2023-10-05
US20250280866A1 (en) 2025-09-11

Similar Documents

Publication Publication Date Title
MX2024012081A (es) Formulaciones de nicotina
DE69208104D1 (de) Orale, osmotische vorrichtung
ES2127745T3 (es) Composiciones para tratamiento de tejidos que comprenden particulas de perfume.
NO915043D0 (no) Osmoseanordning for kontrollert avgivelse av et nyttig middel
ES2134321T3 (es) La preparacion de microesferas proteinicas con gas insoluble encapsulado.
AR052759A1 (es) Dispositivo inhalador de medicamentos
HUP9902477A2 (hu) Folyadékfelszívó és testen viselhető, beültethető, aktív hatóanyagot adagoló eszközök, valamint eljárás az adagolóeszköz készítésére, továbbá vissz-diffúziót szabályozó kilépőcsatorna, féligáteresztő dugó
ES2095043T3 (es) Composicion para preparados orales.
DK1372608T3 (da) Medicinske aerosolformuleringer
PE20061016A1 (es) Una formulacion solida de dosificacion farmaceutica
EP4299651A4 (en) Granular water absorbent, absorbent body containing said water absorbent, and absorbent article using said absorbent body
ES2059495T3 (es) Dispositivo de descarga de farmacos regulado por solubilidad.
UY27027A1 (es) Kit de repinotano
PEREIRA et al. Effect of immersion in various disinfectant solutions on the properties of a heat-cured acrylic resin
AR053977A1 (es) Composiciones farmaceuticas con enmascaramiento de sabor
CO2019011300A2 (es) Composición de infliximab que contiene el sistema de tampón histidina
UY28326A1 (es) Dispositivo de ruptura de liberacion controlada con un pasaje preformado
EP0126791A3 (en) Solid body for the release of perfumes and/or disinfecting agents
MX2021008584A (es) Sistema de blanqueamiento.
Kirby et al. Daily phosphodiesterase type 5 inhibitor therapy: a new treatment option for prostatitis/prostatodynia?
ES2172558T3 (es) Lubricante compatible con radiaciones para dispositivos medicos.
CO2020013679A2 (es) Formulaciones farmacéuticas mejoradas
Rodríguez Varela Trauma y testimonio: la experiencia de Jorge Semprún.
AR004491A1 (es) Composiciones insecticidas de liberacion sostenida.
Sarode et al. The global oral health workforce